Igor Galan, MD
Pain Medicine · Santa Maria, CANPI 1114313087
Payments from drug & device makers
Across 451 payments — averaging $35.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- SK Life Science, Inc.$5K
- Abbott$4K
- AbbVie$2K
- Teva Pharmaceuticals USA, Inc.$1K
- Amgen$557
- Medtronic$400
- plus $3K from 28 others
What the payments were for
- Speaking & faculty fees$2,20014%
- Travel & lodging$2,62316%
- Food & beverage$10,75766%
- Education$6374%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| SK Life Science, Inc. | 65 | $4,907 |
| Abbott | 101 | $3,956 |
| AbbVie(2 entities) | 67 | $1,647 |
| Teva Pharmaceuticals USA, Inc. | 39 | $1,427 |
| Amgen | 34 | $557 |
| Medtronic | 5 | $400 |
| Kyowa Kirin, Inc. | 14 | $320 |
| Sunovion Pharmaceuticals Inc. | 23 | $308 |
| Biotronik NRO, Inc. | 2 | $279 |
| Novartis | 11 | $214 |
| Neurocrine Biosciences, Inc. | 9 | $210 |
| Biohaven Pharmaceutical Holding Company Ltd. | 9 | $206 |
| UCB, Inc. | 9 | $202 |
| Lilly USA, LLC | 9 | $174 |
| Johnson & Johnson | 1 | $173 |
| Nevro Corp. | 1 | $136 |
| Tanabe Pharma America, Inc. | 8 | $133 |
| Almatica Pharma LLC | 5 | $109 |
| Sumitomo Pharma America, Inc. | 6 | $106 |
| Nalu Medical, Inc. | 1 | $102 |
| Supernus Pharmaceuticals, Inc. | 4 | $89 |
| Amneal Pharmaceuticals LLC | 5 | $88 |
| Eisai Inc. | 4 | $84 |
| Tersera Therapeutics LLC | 1 | $70 |
| Biohaven Pharmaceuticals, Inc. | 3 | $61 |
| Scilex Pharmaceuticals Inc. | 3 | $45 |
| Fidia Pharma USA Inc. | 2 | $40 |
| Impel Pharmaceuticals Inc. | 2 | $34 |
| Pfizer | 2 | $31 |
| Genentech USA, Inc. | 1 | $26 |
| Biodelivery Sciences International, Inc. | 2 | $26 |
| Catalyst Pharmaceuticals, Inc. | 1 | $24 |
| Biogen | 1 | $20 |
| Neurelis, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XCOPRI$4,045
- Axium$710
- PROCLAIM$707
- UBRELVY$360
- Prospera$279
- SYNCHROMEDII$241
- QULIPTA$237
- Neuwave$173
- ETERNA$169
- IonicRF$159
- Omnia$136
- AUSTEDO$133
- Proclaim IPG$131
- Accurian$127
- NURTEC ODT$117
- Proclaim Family of SCS IPGs$115
- Austedo XR$115
- Nalu Neurostimulation System$102
How this compares
$16,216 in reported general payments places this provider in the 85th percentile of 840 pain medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XcopriCenobamate | 15 | $24,465 |
| Gabapentin | 616 | $9,305 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 235 | $6,455 |
| NamzaricMemantine Hcl/Donepezil Hcl | 18 | $4,732 |
| Baclofen | 198 | $3,388 |
| Memantine Hcl | 152 | $2,669 |
| Lacosamide | 32 | $2,315 |
| Pregabalin | 73 | $2,206 |
| Levetiracetam | 68 | $1,858 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 57 | $1,778 |
| Diclofenac Sodium | 39 | $1,480 |
| Tizanidine Hcl | 132 | $1,291 |
| Cyclobenzaprine Hcl | 51 | $915 |
| Donepezil Hcl | 95 | $804 |
| Carbamazepine | 15 | $775 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| SK Life Science, Inc.Xcopri | $4,907 | $24,46515 claims |
| AbbVieNamzaric | $1,647 | $4,73218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 840 pain medicine providers in California.
Other pain medicine in Santa Maria
- Eric GrigsbyNapa$3.2M
- Jason PopeSanta Rosa$2.8M
- Javid GhandehariSanta Monica$2.7M
- Alexander HerselThousand Oaks$2.1M
- Krishnan ChakravarthyTemecula$1.9M
- Kasra AmirdelfanWalnut Creek$1.7M
- Ramana NaiduLarkspur$1.6M
- Foead GeulaStudio City$1.3M
- Xiang QianRedwood City$941K
- Jacqueline WeisbeinNapa$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.